Equities Analysts Issue Forecasts for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Soleno Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($1.97) for the year. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Soleno Therapeutics in a report on Monday, December 2nd. Robert W. Baird reaffirmed an “outperform” rating and set a $72.00 target price on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $74.00 price target on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Finally, Oppenheimer upped their price objective on shares of Soleno Therapeutics from $65.00 to $73.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $74.83.

Soleno Therapeutics Price Performance

NASDAQ SLNO opened at $48.29 on Wednesday. The company has a market capitalization of $2.08 billion, a P/E ratio of -14.55 and a beta of -1.47. Soleno Therapeutics has a 12 month low of $36.61 and a 12 month high of $60.92. The company’s 50 day simple moving average is $48.47 and its 200 day simple moving average is $49.63.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22).

Insider Activity

In related news, CFO James H. Mackaness sold 4,083 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $185,409.03. Following the completion of the sale, the chief financial officer now directly owns 115,089 shares in the company, valued at approximately $5,226,191.49. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the completion of the transaction, the chief executive officer now owns 708,616 shares in the company, valued at approximately $32,178,252.56. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,360 shares of company stock worth $790,119. 12.30% of the stock is owned by corporate insiders.

Institutional Trading of Soleno Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SLNO. Amalgamated Bank acquired a new position in Soleno Therapeutics in the 2nd quarter worth about $31,000. Avanza Fonder AB acquired a new position in Soleno Therapeutics in the fourth quarter worth approximately $76,000. Avior Wealth Management LLC bought a new position in Soleno Therapeutics during the fourth quarter valued at approximately $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Soleno Therapeutics during the third quarter valued at approximately $155,000. Finally, Curi RMB Capital LLC bought a new stake in Soleno Therapeutics in the third quarter worth approximately $202,000. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.